Memo Therapeutics increases Series C financing to CHF 45 million

by Ysios Capital

Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF...

Read more

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

by Ysios Capital

The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc.,...

Read more

Ysios Capital joins Neurona 120MUSD financing

by Ysios Capital

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of ...

Read more

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and...

Read more

SpliceBio, backed by Ysios Capital, Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

by Ysios Capital

SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the signing of an exclusive collaboration and licensing agre...

Read more

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing led by Ysios Capital and Gilde Healthcare, to Advance Click-to-Release Therapeutics

by Ysios Capital

Tagworks Pharmaceuticals, the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financing led by Ysios Capit...

Read more

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

by Ysios Capital

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced th...

Read more

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

by Columbus Venture Partners

Minoryx is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chies...

Read more

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

The round was led by RA Capital Management and Andera Partners. Additional new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Cap...

Read more

Minoryx raises €51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

by Caixa Capital Risc

The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...

Read more

NorthSea Therapeutics Completes US$80 Million Series C Fundraising co-led by Ysios Capital to Advance Clinical Programs in Metabolic Disorders

by Ysios Capital

The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc. Existing investors Forbion Ventures, venBi...

Read more

Vifor Pharma to acquire Sanifit, supported, among other investors, by Ysios Capital, Caixa Capital Risc, Columbus Venture Partners and Alta Life Sciences

by Caixa Capital Risc

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

The ICF finances Vicente Torns with €3...

by Institut Català de Finances (ICF)

Founded in 1924, Vicente Torns, headquartered in Rubí, has three fact...

Photos Stream